AKRO — Akero Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00- $4.32bn
- $3.61bn
- 28
- 27
- 77
- 39
Annual balance sheet for Akero Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 268 | 188 | 351 | 550 | 743 |
| Prepaid Expenses | |||||
| Total Current Assets | 271 | 194 | 355 | 560 | 770 |
| Net Property, Plant And Equipment | 1.79 | 1.55 | 1.29 | 1.03 | 0.755 |
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 273 | 196 | 357 | 580 | 826 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Current Liabilities | 13.1 | 25.1 | 19.1 | 19.1 | 39.8 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 14.6 | 26.4 | 30 | 45 | 75.8 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 259 | 169 | 327 | 535 | 750 |
| Total Liabilities & Shareholders' Equity | 273 | 196 | 357 | 580 | 826 |
| Total Common Shares Outstanding |